This application is for the Gynecologic Oncology Group (GOG) CCOP Research Base. The GOG is a nonprofit organization promoting excellence in clinical, translational and basic scientific research in the field of gynecologic malignancies. As the premier world-wide clinical trial group in the prevention and treatment of gynecologic cancers, the GOG has developed an active and productive cancer and prevention control program (CPC). The CPC committee was initiated by the GOG in 1995 and has grown to 46 members with an Executive committee developed in 2005 to better guide the development, activation and completion of phase lib and III clinical trials and observational and clinical translational studies. The CPC Executive Committee membership includes the CPC Committee Co-Chairs, ex-officio NCI-Division of Cancer Prevention representatives (Drs. Minasian and Kelaghan), prevention members (Drs. Byron and Garcia), CCOP members (Drs, Rodriguez and Method), members of the Committees on Experimental Medicine and Healthcare Outcome Research and representatives of the GOG Statistical and Data Center and Administrative Office. Meeting by conference call six times yearly, the CPC Executive Committee oversees the work of the CPC disease-site and discipline subcommittees. The GOG affiliate network is made up of primarily community based institutions working under the supervision of a full member institution. In addition, the GOG serves as a research base for 31 CCOPs and 155 CCOP components that provide national clinical trials in many areas of very limited access. The CCOP leaders have direct input to the research directions of Method leads GOG-0224. The CCOPs provide access to patients, and patients in turn are provided access to high quality clinical trial. In addition to providing a strong environment of cancer prevention and treatment research to the CCOP community, the GOG provides, at each of its meetings, cutting edge, in depth workshops and seminars concerning the scientific underpinning for high quality gynecologic and pre cancer management.

Public Health Relevance

Access to oncology clinical trials is a major concern for patients throughout the United States;and adequate accrual to answer important and relevant questions is critical to an ever improving standard of care for patients. Through its network of CCOP institutions, the GOG is able to provide cancer prevention and control trials leading to education and prevention programs designed to foster earlier detection of gynecologic malignancies, suitable early treatment, and eventual elimination of these cancers as a public health risk.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Gynecologic Oncology Group
United States
Zip Code
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Oliver, Kate E; Brady, William E; Birrer, Michael et al. (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243-249
Mai, Phuong L; Piedmonte, Marion; Han, Paul K et al. (2017) Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:122-129
Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T et al. (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654-1663
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Chan, John K; Brady, Mark F; Penson, Richard T et al. (2016) Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med 374:738-48
Lawrenson, Kate (see original citation for additional authors) (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Hibler, Elizabeth A; Kauderer, James; Greene, Mark H et al. (2016) Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 23:1228-1232
Zeng, Chenjie (see original citation for additional authors) (2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64

Showing the most recent 10 out of 38 publications